We speak with Anthony Tennyson, CEO of Awakn Life Sciences, a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat addiction.
We speak with Anthony Tennyson, CEO of Awakn Life Sciences, a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat addiction.
In our conversation with Anthony, we gain insight on Awakn’s psychedelic therapy delivery activities, the company’s plans to expand across the EU, and what the addition of renowned neuroscientist, Professor David Nutt as their Chief Research Officer means to their ongoing growth initiatives.
*To learn more about the company featured in this episode and the work they’re doing, visit their website: AwaknLifeSciences.com
